This Class I recall covers more than 130,000 different devices, according to the FDA. 

Low levels of residual mitral regurgitation after TEER can make a big impact on patient outcomes, researchers explained in a new analysis. 

The company also announced that two specialists with more than 25 years of industry experience have joined its leadership team. 

Researchers called for better guidelines that cover when clinicians should consider stopping anticoagulation therapy for patients with AFib. The risks of such medication, they observed, may often outweigh the benefits.